BRNS (Barinthus Biotherapeutics) Total Assets : $160.33 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Barinthus Biotherapeutics Total Assets?

Barinthus Biotherapeutics's Total Assets for the quarter that ended in Dec. 2024 was $160.33 Mil.

During the past 12 months, Barinthus Biotherapeutics's average Total Assets Growth Rate was -31.40% per year. During the past 3 years, the average Total Assets Growth Rate was -9.30% per year. During the past 5 years, the average Total Assets Growth Rate was 59.50% per year.

During the past 6 years, Barinthus Biotherapeutics's highest 3-Year average Total Assets Growth Rate was 115.20%. The lowest was -9.30%. And the median was 113.90%.

Total Assets is connected with ROA %. Barinthus Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2024 was -47.08%. Total Assets is also linked to Revenue through Asset Turnover. Barinthus Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2024 was 0.00.

Barinthus Biotherapeutics Total Assets Historical Data

The historical data trend for Barinthus Biotherapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Barinthus Biotherapeutics Total Assets Chart

Barinthus Biotherapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

50.67

280.72

270.21

214.51

160.33

Barinthus Biotherapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Assets	Get a 7-Day Free Trial															214.51	199.48	186.75	188.69	160.33

Barinthus Biotherapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Barinthus Biotherapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	130.135	+	30.192
	=	160.33

Barinthus Biotherapeutics's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (Q: Dec. 2024 )	+	Total Liabilities (Q: Dec. 2024 )
	=	130.135	+	30.192
	=	160.33

Barinthus Biotherapeutics (NAS:BRNS) Total Assets Explanation

Total Assets is connected with ROA %.

Barinthus Biotherapeutics's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %	=	Net Income (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
	=	-82.16	/	( (188.689	+	160.327)	/ 2 )
	=	-82.16	/	174.508
	=	-47.08 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Barinthus Biotherapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is

	Asset Turnover
=	Revenue (Q: Dec. 2024 )	/	( (Total Assets (Q: Sep. 2024 )	+	Total Assets (Q: Dec. 2024 ))	/ count )
=	0	/	( (188.689	+	160.327)	/ 2 )
=	0	/	174.508
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Barinthus Biotherapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Barinthus Biotherapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Barinthus Biotherapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Barinthus Biotherapeutics PLC (NAS:BRNS) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 6-10, Rutherford Avenue, Zeus Building, Harwell, GBR, OX11 0DF

Website

https://www.barinthusbio.com

Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic that guide the immune system to overcome chronic infectious diseases, autoimmunity and cancer.

Executives

Joseph Scheeren	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Robin Wright	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
William Enright	director, officer: Chief Executive Officer	910 CLOPPER ROAD, SUITE 201S, GAITHERSBURG MD 20878
Nadege Pelletier	officer: Chief Scientific Officer	C/O VACCITECH PLC, UNIT 6-10, ZEUS BUILDING RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Gemma Brown	officer: Chief Financial Officer	VACCITECH PLC, UNIT 6-10, ZEUS BUILDING, RUTHERFORD AVENUE, HARWELL, DIDCOT X0 OX11 0DF
Graham Griffiths	officer: Chief Business Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Christopher Ellis	officer: Chief Operating Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Oxford Science Enterprises Plc	10 percent owner	46 WOODSTOCK ROAD, OXFORD X0 OX2 6HT
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Pierre A. Morgon	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Margaret Marshall	officer: Chief Medical Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Thomas George Evans	officer: Chief Scientific Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Alex Hammacher	director	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE
Georgy Egorov	officer: Chief Financial Officer	THE SCHRODINGER BUILDING, HEATLEY ROAD, THE OXFORD SCIENCE PARK, OXFORD X0 OX4 4GE